{"transactions":[{"id":2048480,"issuer":{"id":108681,"kind":"organization","name":"Old Ayala, Inc","symbol":"ADXS"},"owners":[{"id":120543,"kind":"person","name":"Maimon Yossi","position":1,"cik":"0001385115","reported_name":"Maimon Yossi","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, Secretary and Treasurer"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-23T21:00:26.000Z","date":"2023-01-19","kind":"disposition_to_issuer","acquired":false,"shares":31950,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of that certain Agreement and Plan of Merger, dated October 18, 2022, by and among Ayala Pharmaceuticals, Inc. (\"Ayala\"), Advaxis, Inc. (\"Advaxis\"), and DOE Merger Sub, Inc., a wholly owned subsidiary of Advaxis (the \"Merger Agreement\"). The acquisition is more fully described in Ayala's definitive proxy statement filed with the Securities and Exchange Commission on December 12, 2022. (Continued below.)"},{"field":"shares","element":"transactionShares","label":"F2","text":"(Continued from above.) In accordance with the terms of the Merger Agreement, each share of Ayala's common stock (the \"Ayala Common Stock\"), including restricted stock, was cancelled and converted into the right to receive 0.1874 shares (the \"Exchange Ratio\") of Advaxis common stock (the \"Advaxis Common Stock\"). All Ayala restricted stock awards that were outstanding immediately prior to the effective time of the merger were substituted and converted automatically into the right to receive a number of shares of restricted Advaxis Common Stock equal to the Exchange Ratio. In accordance with a letter agreement between the Reporting Person and Ayala, each share of restricted stock held by the Reporting Person vested in full."},{"field":"shares","element":"transactionShares","label":"F3","text":"Each outstanding option to purchase Ayala Common Stock (each, an \"Ayala Option\") was substituted and converted automatically into an option (each, an \"Advaxis Replacement Option\") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. In accordance with a letter agreement between the Reporting Person and Ayala, each option held by the Reporting Person vested in full."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each outstanding option to purchase Ayala Common Stock (each, an \"Ayala Option\") was substituted and converted automatically into an option (each, an \"Advaxis Replacement Option\") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. In accordance with a letter agreement between the Reporting Person and Ayala, each option held by the Reporting Person vested in full."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each outstanding option to purchase Ayala Common Stock (each, an \"Ayala Option\") was substituted and converted automatically into an option (each, an \"Advaxis Replacement Option\") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. In accordance with a letter agreement between the Reporting Person and Ayala, each option held by the Reporting Person vested in full."}],"balance_after":0,"derivative":{"exercise_price":9.105,"expiration_date":"2032-01-02","underlying":"Common Stock","underlying_shares":31950},"source":{"system":"sec-edgar","filing":"0001213900-23-004543","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1385115/000121390023004543/ownership.xml","form_type":"4"}},{"id":2048479,"issuer":{"id":108681,"kind":"organization","name":"Old Ayala, Inc","symbol":"ADXS"},"owners":[{"id":120543,"kind":"person","name":"Maimon Yossi","position":1,"cik":"0001385115","reported_name":"Maimon Yossi","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, Secretary and Treasurer"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-23T21:00:26.000Z","date":"2023-01-19","kind":"disposition_to_issuer","acquired":false,"shares":19170,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of that certain Agreement and Plan of Merger, dated October 18, 2022, by and among Ayala Pharmaceuticals, Inc. (\"Ayala\"), Advaxis, Inc. (\"Advaxis\"), and DOE Merger Sub, Inc., a wholly owned subsidiary of Advaxis (the \"Merger Agreement\"). The acquisition is more fully described in Ayala's definitive proxy statement filed with the Securities and Exchange Commission on December 12, 2022. (Continued below.)"},{"field":"shares","element":"transactionShares","label":"F2","text":"(Continued from above.) In accordance with the terms of the Merger Agreement, each share of Ayala's common stock (the \"Ayala Common Stock\"), including restricted stock, was cancelled and converted into the right to receive 0.1874 shares (the \"Exchange Ratio\") of Advaxis common stock (the \"Advaxis Common Stock\"). All Ayala restricted stock awards that were outstanding immediately prior to the effective time of the merger were substituted and converted automatically into the right to receive a number of shares of restricted Advaxis Common Stock equal to the Exchange Ratio. In accordance with a letter agreement between the Reporting Person and Ayala, each share of restricted stock held by the Reporting Person vested in full."},{"field":"shares","element":"transactionShares","label":"F3","text":"Each outstanding option to purchase Ayala Common Stock (each, an \"Ayala Option\") was substituted and converted automatically into an option (each, an \"Advaxis Replacement Option\") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. In accordance with a letter agreement between the Reporting Person and Ayala, each option held by the Reporting Person vested in full."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each outstanding option to purchase Ayala Common Stock (each, an \"Ayala Option\") was substituted and converted automatically into an option (each, an \"Advaxis Replacement Option\") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. In accordance with a letter agreement between the Reporting Person and Ayala, each option held by the Reporting Person vested in full."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each outstanding option to purchase Ayala Common Stock (each, an \"Ayala Option\") was substituted and converted automatically into an option (each, an \"Advaxis Replacement Option\") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. In accordance with a letter agreement between the Reporting Person and Ayala, each option held by the Reporting Person vested in full."}],"balance_after":0,"derivative":{"exercise_price":11.26,"expiration_date":"2031-01-03","underlying":"Common Stock","underlying_shares":19170},"source":{"system":"sec-edgar","filing":"0001213900-23-004543","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1385115/000121390023004543/ownership.xml","form_type":"4"}},{"id":2048478,"issuer":{"id":108681,"kind":"organization","name":"Old Ayala, Inc","symbol":"ADXS"},"owners":[{"id":120543,"kind":"person","name":"Maimon Yossi","position":1,"cik":"0001385115","reported_name":"Maimon Yossi","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, Secretary and Treasurer"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-23T21:00:26.000Z","date":"2023-01-19","kind":"disposition_to_issuer","acquired":false,"shares":9460,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of that certain Agreement and Plan of Merger, dated October 18, 2022, by and among Ayala Pharmaceuticals, Inc. (\"Ayala\"), Advaxis, Inc. (\"Advaxis\"), and DOE Merger Sub, Inc., a wholly owned subsidiary of Advaxis (the \"Merger Agreement\"). The acquisition is more fully described in Ayala's definitive proxy statement filed with the Securities and Exchange Commission on December 12, 2022. (Continued below.)"},{"field":"shares","element":"transactionShares","label":"F2","text":"(Continued from above.) In accordance with the terms of the Merger Agreement, each share of Ayala's common stock (the \"Ayala Common Stock\"), including restricted stock, was cancelled and converted into the right to receive 0.1874 shares (the \"Exchange Ratio\") of Advaxis common stock (the \"Advaxis Common Stock\"). All Ayala restricted stock awards that were outstanding immediately prior to the effective time of the merger were substituted and converted automatically into the right to receive a number of shares of restricted Advaxis Common Stock equal to the Exchange Ratio. In accordance with a letter agreement between the Reporting Person and Ayala, each share of restricted stock held by the Reporting Person vested in full."},{"field":"shares","element":"transactionShares","label":"F3","text":"Each outstanding option to purchase Ayala Common Stock (each, an \"Ayala Option\") was substituted and converted automatically into an option (each, an \"Advaxis Replacement Option\") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. In accordance with a letter agreement between the Reporting Person and Ayala, each option held by the Reporting Person vested in full."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each outstanding option to purchase Ayala Common Stock (each, an \"Ayala Option\") was substituted and converted automatically into an option (each, an \"Advaxis Replacement Option\") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. In accordance with a letter agreement between the Reporting Person and Ayala, each option held by the Reporting Person vested in full."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each outstanding option to purchase Ayala Common Stock (each, an \"Ayala Option\") was substituted and converted automatically into an option (each, an \"Advaxis Replacement Option\") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. In accordance with a letter agreement between the Reporting Person and Ayala, each option held by the Reporting Person vested in full."}],"balance_after":0,"derivative":{"exercise_price":6.5,"expiration_date":"2029-12-24","underlying":"Common Stock","underlying_shares":9460},"source":{"system":"sec-edgar","filing":"0001213900-23-004543","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1385115/000121390023004543/ownership.xml","form_type":"4"}},{"id":2048477,"issuer":{"id":108681,"kind":"organization","name":"Old Ayala, Inc","symbol":"ADXS"},"owners":[{"id":120543,"kind":"person","name":"Maimon Yossi","position":1,"cik":"0001385115","reported_name":"Maimon Yossi","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, Secretary and Treasurer"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-23T21:00:26.000Z","date":"2023-01-19","kind":"disposition_to_issuer","acquired":false,"shares":70500,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of that certain Agreement and Plan of Merger, dated October 18, 2022, by and among Ayala Pharmaceuticals, Inc. (\"Ayala\"), Advaxis, Inc. (\"Advaxis\"), and DOE Merger Sub, Inc., a wholly owned subsidiary of Advaxis (the \"Merger Agreement\"). The acquisition is more fully described in Ayala's definitive proxy statement filed with the Securities and Exchange Commission on December 12, 2022. (Continued below.)"},{"field":"shares","element":"transactionShares","label":"F2","text":"(Continued from above.) In accordance with the terms of the Merger Agreement, each share of Ayala's common stock (the \"Ayala Common Stock\"), including restricted stock, was cancelled and converted into the right to receive 0.1874 shares (the \"Exchange Ratio\") of Advaxis common stock (the \"Advaxis Common Stock\"). All Ayala restricted stock awards that were outstanding immediately prior to the effective time of the merger were substituted and converted automatically into the right to receive a number of shares of restricted Advaxis Common Stock equal to the Exchange Ratio. In accordance with a letter agreement between the Reporting Person and Ayala, each share of restricted stock held by the Reporting Person vested in full."},{"field":"shares","element":"transactionShares","label":"F3","text":"Each outstanding option to purchase Ayala Common Stock (each, an \"Ayala Option\") was substituted and converted automatically into an option (each, an \"Advaxis Replacement Option\") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. In accordance with a letter agreement between the Reporting Person and Ayala, each option held by the Reporting Person vested in full."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each outstanding option to purchase Ayala Common Stock (each, an \"Ayala Option\") was substituted and converted automatically into an option (each, an \"Advaxis Replacement Option\") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. In accordance with a letter agreement between the Reporting Person and Ayala, each option held by the Reporting Person vested in full."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each outstanding option to purchase Ayala Common Stock (each, an \"Ayala Option\") was substituted and converted automatically into an option (each, an \"Advaxis Replacement Option\") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. In accordance with a letter agreement between the Reporting Person and Ayala, each option held by the Reporting Person vested in full."}],"balance_after":0,"derivative":{"exercise_price":5.16,"expiration_date":"2029-03-15","underlying":"Common Stock","underlying_shares":70500},"source":{"system":"sec-edgar","filing":"0001213900-23-004543","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385115/000121390023004543/ownership.xml","form_type":"4"}},{"id":2048476,"issuer":{"id":108681,"kind":"organization","name":"Old Ayala, Inc","symbol":"ADXS"},"owners":[{"id":120543,"kind":"person","name":"Maimon Yossi","position":1,"cik":"0001385115","reported_name":"Maimon Yossi","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, Secretary and Treasurer"}}],"security":"Common Stock","published_at":"2023-01-23T21:00:26.000Z","date":"2023-01-19","kind":"disposition_to_issuer","acquired":false,"shares":69872,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of that certain Agreement and Plan of Merger, dated October 18, 2022, by and among Ayala Pharmaceuticals, Inc. (\"Ayala\"), Advaxis, Inc. (\"Advaxis\"), and DOE Merger Sub, Inc., a wholly owned subsidiary of Advaxis (the \"Merger Agreement\"). The acquisition is more fully described in Ayala's definitive proxy statement filed with the Securities and Exchange Commission on December 12, 2022. (Continued below.)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from above.) In accordance with the terms of the Merger Agreement, each share of Ayala's common stock (the \"Ayala Common Stock\"), including restricted stock, was cancelled and converted into the right to receive 0.1874 shares (the \"Exchange Ratio\") of Advaxis common stock (the \"Advaxis Common Stock\"). All Ayala restricted stock awards that were outstanding immediately prior to the effective time of the merger were substituted and converted automatically into the right to receive a number of shares of restricted Advaxis Common Stock equal to the Exchange Ratio. In accordance with a letter agreement between the Reporting Person and Ayala, each share of restricted stock held by the Reporting Person vested in full."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001213900-23-004543","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385115/000121390023004543/ownership.xml","form_type":"4"}},{"id":2269892,"issuer":{"id":108681,"kind":"organization","name":"Old Ayala, Inc","symbol":"ADXS"},"owners":[{"id":120543,"kind":"person","name":"Maimon Yossi","position":1,"cik":"0001385115","reported_name":"Maimon Yossi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, Secretary & Treasurer"}}],"security":"Common Stock","published_at":"2022-05-16T16:10:46.000Z","date":"2022-05-16","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted common stock, which will vest quarterly over a period of three years from May 16, 2022."}],"balance_after":69872,"source":{"system":"sec-edgar","filing":"0000899243-22-018135","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385115/000089924322018135/doc4.xml","form_type":"4"}},{"id":2442990,"issuer":{"id":108681,"kind":"organization","name":"Old Ayala, Inc","symbol":"ADXS"},"owners":[{"id":120543,"kind":"person","name":"Maimon Yossi","position":1,"cik":"0001385115","reported_name":"Maimon Yossi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, Secretary & Treasurer"}}],"security":"Stock Option","published_at":"2022-01-05T16:05:36.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":31950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests and becomes exercisable in sixteen substantially equal quarterly installments from the grants date, such that the option shall be fully vested on January 3, 2026."}],"balance_after":31950,"derivative":{"exercise_price":9.105,"expiration_date":"2032-01-02","underlying":"Common Stock","underlying_shares":31950},"source":{"system":"sec-edgar","filing":"0000899243-22-000877","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385115/000089924322000877/doc4.xml","form_type":"4"}},{"id":2914821,"issuer":{"id":108681,"kind":"organization","name":"Old Ayala, Inc","symbol":"ADXS"},"owners":[{"id":120543,"kind":"person","name":"Maimon Yossi","position":1,"cik":"0001385115","reported_name":"Maimon Yossi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, Secretary & Treasurer"}}],"security":"Stock Option","published_at":"2021-01-06T16:05:13.000Z","date":"2021-01-04","kind":"grant","acquired":true,"shares":19170,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests and becomes exercisable in sixteen substantially equal quarterly installments from the grants date, such that the option shall be fully vested on January 4, 2025."}],"balance_after":19170,"derivative":{"exercise_price":11.26,"expiration_date":"2031-01-03","underlying":"Common Stock","underlying_shares":19170},"source":{"system":"sec-edgar","filing":"0000899243-21-000681","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385115/000089924321000681/doc4.xml","form_type":"4"}},{"id":2914820,"issuer":{"id":108681,"kind":"organization","name":"Old Ayala, Inc","symbol":"ADXS"},"owners":[{"id":120543,"kind":"person","name":"Maimon Yossi","position":1,"cik":"0001385115","reported_name":"Maimon Yossi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, Secretary & Treasurer"}}],"security":"Common Stock","published_at":"2021-01-06T16:05:13.000Z","date":"2021-01-04","kind":"grant","acquired":true,"shares":8520,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":19872,"source":{"system":"sec-edgar","filing":"0000899243-21-000681","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385115/000089924321000681/doc4.xml","form_type":"4"}},{"id":3154061,"issuer":{"id":108681,"kind":"organization","name":"Old Ayala, Inc","symbol":"ADXS"},"owners":[{"id":120543,"kind":"person","name":"Maimon Yossi","position":1,"cik":"0001385115","reported_name":"Maimon Yossi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, Secretary & Treasurer"}}],"security":"Common Stock","published_at":"2020-05-11T17:39:47.000Z","date":"2020-05-07","kind":"grant","acquired":true,"shares":11352,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock, which will vest as to 25% of the shares on May 7, 2021 and as to the remaining shares in 12 quarterly installments thereafter."}],"balance_after":11352,"source":{"system":"sec-edgar","filing":"0000899243-20-012600","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385115/000089924320012600/doc4.xml","form_type":"4"}},{"id":3816210,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":120543,"kind":"person","name":"Maimon Yossi","position":1,"cik":"0001385115","reported_name":"Maimon Yossi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Financial Officer"}}],"security":"Stock Options (Right to Buy)","published_at":"2018-09-14T20:31:39.000Z","date":"2018-09-13","kind":"grant","acquired":true,"shares":700000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include (i) options to purchase 130,000 shares of common stock at an exercise price equal to $6.90 per share that expire on February 25, 2020; and (ii) options to purchase 250,000 shares of common stock at an exercise price equal to $1.72 per share that expire on March 23, 2025."}],"balance_after":700000,"derivative":{"exercise_price":0.56,"expiration_date":"2028-09-13","underlying":"Common Stock","underlying_shares":700000},"source":{"system":"sec-edgar","filing":"0001144204-18-049524","document":"tv502884_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000114420418049524/tv502884_4.xml","form_type":"4"}}]}